BofA reinstates pharma coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Deutsche Bank Reiterates Hold Rating on Gilead Sciences (GILD)
December 11, 2024 6:31 AM ESTDeutsche Bank analyst James Shin reiterated a Hold rating and $73.00 price target on Gilead Sciences (NASDAQ: GILD).
The analyst comments "Big picture - GILD's HIV day demonstrated its HIV franchise has potential to extend into FY2035. GILD is trading at ~12x the Street's 2025E EPS ($7.47/sh), >2- turns... More
Pfizer (PFE) PT Lowered to $28 at Leerink Partners
December 11, 2024 6:24 AM ESTLeerink Partners analyst David Risinger lowered the price target on Pfizer (NYSE: PFE) to $28.00 (from $31.00) while maintaining a Market Perform rating.
The analyst comments "We are lowering our 25E EPS by 10% from $3.12 to $2.82 ahead of the company's 2025 guidance call on Dec 17 at 8:30 am ET; webcast... More
Gilead Sciences (GILD) PT Raised to $99 at Leerink Partners
December 11, 2024 6:21 AM ESTLeerink Partners analyst Andrew Berens raised the price target on Gilead Sciences (NASDAQ: GILD) to $99.00 (from $96.00) while maintaining a Outperform rating.
The analyst comments "Leaving Gileads HIV investors event, we reaffirm our optimism that Gilead can appreciably mitigate the impact of Biktarvys... More
